The Firm represented New Mountain Capital in connection with its majority investment in Covaris. Financial terms of the transaction were not disclosed.
Covaris develops, manufactures and markets instruments, consumables and reagents used in pre-analytical sample preparation for genomic and proteomic analysis to help accelerate the pace of research and life science innovations. Some of the non-contact applications include faster automated DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension and compound formulation.
The Simpson Thacher team included Elizabeth Cooper, Matthew Rogers and Christopher Scavone (M&A); Vanessa Burrows and Tera Rule (Healthcare Regulatory); Christopher Brown, Benjamin Persina, Noah DeBlasi, Mark Haddox, Cem Islikci and Daniel Levine (Credit); Andrew Purcell, Dmitry Zelik and Adam Hersch (Tax); Andrew Blau, Ryan Stott and Hannah Daniels (Executive Compensation & Employee Benefits); Lori Lesser, Alysha Sekhon and Samuel Watters (IP); and Adeeb Fadil and Noreen Lavan (Environmental).